论文部分内容阅读
目的探讨沐舒坦用于呼吸系统疾病患者雾化吸入的效果。方法将80例雾化吸入患者随机分为观察组与对照组各40例。观察组采用沐舒坦注射液15 mg加生理盐水10 ml进行雾化吸入,对照组采用庆大霉素8万U、α-糜蛋白酶4 000 U和地塞米松5 mg雾化吸入。治疗3 d评价疗效。结果观察组患者咽部充血、咽痛、咳嗽及咳痰改善情况显著优于对照组(均P<0.05)。结论沐舒坦雾化吸入有利于降低痰液的粘稠度,促进痰液排出,从而减轻咳嗽症状。
Objective To explore the effect of mucosolvan inhalation for patients with respiratory diseases. Methods Eighty inhaled patients were randomly divided into observation group and control group, 40 cases each. In the observation group, mucosolvan injection 15 mg and saline 10 ml were used for inhalation. In the control group, gentamycin 80,000 U, α-chymotrypsin 4 000 U and dexamethasone 5 mg were inhaled. Treatment of 3 d evaluation of curative effect. Results The improvement of throat congestion, sore throat, cough and expectoration of the observation group was significantly better than that of the control group (all P <0.05). Conclusion Mucosolvan inhalation is conducive to reduce the viscosity of sputum and promote sputum discharge, thereby reducing the symptoms of cough.